Hs.KRAS4b G12D Citations (4)
Originally described in: RAS mutant collection V2.0Esposito unpublished
Articles Citing Hs.KRAS4b G12D
Articles |
---|
A systems mechanism for KRAS mutant allele-specific responses to targeted therapy. McFall T, Diedrich JK, Mengistu M, Littlechild SL, Paskvan KV, Sisk-Hackworth L, Moresco JJ, Shaw AS, Stites EC. Sci Signal. 2019 Sep 24;12(600). pii: 12/600/eaaw8288. doi: 10.1126/scisignal.aaw8288. PubMed |
The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer. Lee SH, Jeon Y, Kang JH, Jang H, Lee H, Kim SY. Cancers (Basel). 2020 May 28;12(6). pii: cancers12061382. doi: 10.3390/cancers12061382. PubMed |
Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. McFall T, Stites EC. Cell Rep. 2021 Dec 14;37(11):110096. doi: 10.1016/j.celrep.2021.110096. PubMed |
Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. Glorieux C, Xia X, You X, Wang Z, Han Y, Yang J, Noppe G, Meester C, Ling J, Robert A, Zhang H, Li SP, Wang H, Chiao PJ, Zhang L, Li X, Huang P. J Adv Res. 2022 Sep;40:109-124. doi: 10.1016/j.jare.2021.12.005. Epub 2021 Dec 21. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.